Jeff Yass’s Crescent Biopharma CBIO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-1,161
Closed -$348K 12467
2024
Q1
$348K Buy
1,161
+989
+575% +$295K ﹤0.01% 9359
2023
Q4
$40.6K Sell
172
-35
-17% -$5.44K ﹤0.01% 11793
2023
Q3
$31.1K Sell
207
-201
-49% -$31.7K ﹤0.01% 11475
2023
Q2
$71K Buy
408
+183
+81% +$30.7K ﹤0.01% 11173
2023
Q1
$28.4K Buy
+225
New +$50.6K ﹤0.01% 11936
2022
Q1
Sell
-2,465
Closed -$355K 13366
2021
Q4
$355K Buy
2,465
+256
+12% +$46.5K ﹤0.01% 10078
2021
Q3
$484K Sell
2,209
-727
-25% -$154K ﹤0.01% 9479
2021
Q2
$681K Buy
2,936
+902
+44% +$230K ﹤0.01% 8813
2021
Q1
$612K Buy
2,034
+786
+63% +$282K ﹤0.01% 9011
2020
Q4
$469K Buy
1,248
+685
+122% +$240K ﹤0.01% 8423
2020
Q3
$173K Sell
563
-84
-13% -$32.1K ﹤0.01% 9586
2020
Q2
$243K Buy
+647
New +$183K ﹤0.01% 8704
2019
Q3
Sell
-118
Closed -$141K 10403
2019
Q2
$141K Sell
118
-38
-24% -$45.4K ﹤0.01% 9417
2019
Q1
$194K Buy
+156
New +$179K ﹤0.01% 7898
2018
Q4
Sell
-124
Closed -$179K 9297
2018
Q3
$179K Sell
124
-142
-53% -$215K ﹤0.01% 8304
2018
Q2
$429K Sell
266
-313
-54% -$538K ﹤0.01% 7104
2018
Q1
$940K Sell
579
-730
-56% -$1.52M ﹤0.01% 5369
2017
Q4
$2.2M Buy
1,309
+1,172
+855% +$1.55M ﹤0.01% 3740
2017
Q3
$192K Sell
137
-862
-86% -$1.01M ﹤0.01% 8043
2017
Q2
$1.11M Buy
+999
New +$825K ﹤0.01% 5028

Other funds holding CBIO

Jeff Yass's CBIO Position: Q2 2026 in Review

Jeff Yass sold out of Crescent Biopharma (CBIO) in Q2 2026, closing a stake of 213,635 shares — an estimated $3.92M sold.

Jeff Yass first reported a position in CBIO in Q2 2017 and held it in 26 quarters. The position peaked at $3.92M in Q1 2026. 81 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Jeff Yass reported no remaining Crescent Biopharma position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 213,635 Crescent Biopharma shares in Q2 2026, an estimated $3.92M.
  • Jeff Yass first reported a position in Crescent Biopharma in Q2 2017 and held it in 26 quarters.
  • Jeff Yass's Crescent Biopharma position peaked at $3.92M in Q1 2026.
  • 81 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.